Summary

3.94 -0.06(-1.51%)09/13/2024
PermRock Royalty Trust (PRT)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 YearsAll Time
-1.502.60-1.014.23-11.26-39.20-27.27-61.43


Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1


Trading Data
Close3.94
Open4.04
High4.07
Low3.93
Volume46,166
Change-0.06
Change %-1.50
Avg Volume (20 Days)49,681
Volume/Avg Volume (20 Days) Ratio0.93
52 Week Range3.58 - 6.99
Price vs 52 Week High-43.63%
Price vs 52 Week Low10.06%
Range-2.48
Gap Up/Down0.02
Fundamentals
Market Capitalization (Mln)48
EBIDTA0
PE Ratio14.6269
PEG Ratio0.0000
WallStreet Target Price2.00
Book Value7.0560
Earnings Per Share0.4690
EPS Estimate Current Quarter0.0000
EPS Estimate Next Quarter0.0000
EPS Estimate Current Year0.0000
EPS Estimate Next Year0.0000
Diluted EPS (TTM)0.4690
Revenues
Profit Marging0.8823
Operating Marging (TTM)0.8823
Return on asset (TTM)0.0406
Return on equity (TTM)0.0652
Revenue TTM6,464,161
Revenue per share TTM0.5310
Quarterly Revenue Growth (YOY)5.9510
Quarterly Earnings Growth (YOY)16.2740
Gross Profit (TTM)3,188,156
Dividends
Dividend Share0.4690
Dividend Yield0.0678
Valuations
Trailing PE14.6269
Forward PE10.2775
Price Sales (TTM)0.0000
Price Book (MRQ)0.9949
Revenue Enterprise Value 12.9628
EBITDA Enterprise Value14.6917
Shares
Shares Outstanding12,165,700
Shares Float12,156,973
Shares Short0
Shares Short (Prior Month)0
Shares Ratio0.00
Short Outstanding (%)0.00
Short Float (%)0.00
Insider (%)0.07
Institutions (%)48.75


09/13 10:00 EST - globenewswire.com
Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
-  Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation
08/20 06:30 EST - prnewswire.com
PermRock Royalty Trust Declares Monthly Cash Distribution
DALLAS , Aug. 20, 2024 /PRNewswire/ -- PermRock Royalty Trust (NYSE:PRT) (the "Trust") today declared a monthly cash distribution to record holders of its trust units representing beneficial interests in the Trust ("Trust Units") as of August 30, 2024, and payable on September 16, 2024, in the amount of $488,593.20 ($0.040161 per Trust Unit), based principally upon production during the month of June 2024. The following table displays underlying oil and natural gas sales volumes and average received wellhead prices attributable to the current and prior month net profits interest calculations: Underlying Sales Volumes Average Price Oil Natural Gas Oil Natural Gas Bbls Bbls/D Mcf Mcf/D (per Bbl) (per Mcf) Current Month 22,761 759 30,104 1,003 $76.91 $2.09 Prior Month 24,389 787 30,833 995 $78.30 $1.88 Oil cash receipts for the properties underlying the Trust totaled $1.75 million for the current month, a decrease of $0.16 million from the prior month's distribution period.
07/09 07:30 EST - globenewswire.com
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two mechanisms .
12/27 08:52 EST - 247wallst.com
6 Dividend Stocks I Wouldn't Touch With a 10 Foot Pole
The company owns a 75% net overriding royalty interest in the Waddell Ranch properties comprising Dune, Sand Hills (Judkins) Sand Hills (McKnight) Sand Hills (Tubb) University-Waddell (Devonian) Waddell Fields is located in Crane County, Texas.
07/17 13:47 EST - seekingalpha.com
87 Monthly Paying Dividend Stocks And 80 Funds For July
Imagine stocks or funds that pay out their dividends once-a-month! Unlike waiting for quarterly, semi-annual or (ugh) annual payouts, your angst waiting for money is reduced by 300%, or more! These July U.S. exchange-traded monthly-paid (MoPay) dividends, upsides, and net-gains include: 1. Stocks by-yield (87); 2. Stocks by price-upside (30); 3. Closed-End-Investments, Exchange-Traded-Funds & Notes (CEICs/ETFs/ETNs) by-yield >8.74% (80). Items: 1. Top MoPay stock gains; 2. Overall best MoPay gainers; 3. Funds vs.Equities; 4. Fund risks/rewards. All per prices as of 7/13/23.
04/13 17:01 EST - investorplace.com
7 Blue-Chip Stocks That Pay You Monthly Dividends
Generally speaking, investing in blue-chip stocks that pay monthly dividends has several advantages. The most obvious advantage, and one that's particularly attractive currently, is income.
03/27 15:54 EST - investorplace.com
7 Monthly Dividend Stocks to Buy During the Market Jitters
With banking sector fears once again dominating headlines, investors should consider the consistent passive income potential of monthly dividend stocks to buy. Typically, companies that provide passive income do so on a quarterly basis.